Watch Dr. Brenner explain the importance of recognizing and treating multiple symptoms of IBS-D

Darren M. Brenner, MD

Associate Professor of Medicine and Surgery
Irene D. Pritzker Foundation Research Scholar, Director
Northwestern Neurogastromotility and Integrated Bowel Dysfunction Programs, Director
Motts Tonelli GI Physiology Laboratory, Northwestern University Feinberg School of Medicine

In this video, Dr. Brenner discusses the importance of recognizing and treating multiple symptoms of IBS-D.


XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.

  • XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.
  • Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including XIFAXAN, and may range in severity from mild diarrhea to fatal colitis. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued.